Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. (EPRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
eprx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Eupraxia Pharmaceuticals Inc. (EPRX) measures how much investors pay for each dollar of the company's trailing earnings. EPRX's current PE ratio of N/A is calculated by dividing its stock price of $6.13 by its TTM earnings per share of -$0.74.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc.You EPRX | $205M | N/A | — | -$0.74 |
 Aardvark Therapeutics, Inc. Common Stock AARD | $79M | N/A | — | -$2.64 |
 Genfit S.A. GNFT | $446M | 119.75x | — | $0.03 |
 Inventiva S.A. IVA | $202M | N/A | — | -$1.82 |
 MediWound Ltd. MDWD | $154M | N/A | — | -$2.10 |
 Nautilus Biotechnology, Inc. NAUT | $298M | N/A | — | -$0.47 |
 Neonc Technologies Holdings, Inc. NTHI | $96M | N/A | — | -$3.23 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.35 | — | |
2024-12-31 FY2024 | — | $-0.75 | — | |
2023-12-31 FY2023 | — | $-0.88 | — | |
2022-12-31 FY2022 | — | $-0.96 | — | |
2021-12-31 FY2021 | — | $-1.27 | — | |
2020-12-31 FY2020 | — | $-0.31 | — | |
2019-12-31 FY2019 | — | $-0.57 | — | |
2018-12-31 FY2018 | — | $-1.03 | — | |
2017-12-31 FY2017 | — | $-0.34 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Eupraxia Pharmaceuticals Inc. (EPRX) measures how much investors pay for each dollar of the company's trailing earnings. EPRX's current PE ratio of N/A is calculated by dividing its stock price of $6.13 by its TTM earnings per share of -$0.74.
Frequently asked questions
EPRX pe ratio · 6 questionsEPRX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $6.13 and TTM EPS of -$0.74. Data sourced from Financial Modeling Prep via EPRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Eupraxia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08